Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 6—June 2011


Cefepime-Resistant Pseudomonas aeruginosa

Ehimare Akhabue, Marie Synnestvedt, Mark G. Weiner, Warren B. Bilker, and Ebbing LautenbachComments to Author 
Author affiliations: Author affiliation: University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Main Article

Table 2

Multivariable model of risk factors for cefepime-resistant Pseudomonas aeruginosa infection, Philadelphia, PA, USA, 2001–2006*

Variable Unadjusted OR Adjusted OR (95% CI) p value
Prior use of extended-spectrum cephalosporin 2.87 2.18 (1.57–3.04) <0.001
Prior use of extended-spectrum penicillin 2.99 1.91 (1.22–2.99) 0.005
Prior use of quinolone 2.61 1.96 (1.38–2.78) <0.001
Prior use of carbapenem 2.74 1.70 (0.90–3.21) 0.10
Transfer from outside facility 1.85 1.49 (1.09–2.04) 0.01
Length of hospital stay before culture NA 1.00 (0.99–1.01)† 0.81

*OR, odds ratio; CI, confidence interval; NA, not applicable. No substantive changes were found when above analyses were limited to bloodstream isolates only.
†Odds associated with each 1-day increase in hospital stay.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO